Mechanism
GHK is a naturally occurring tripeptide (glycine–histidine–lysine) that binds copper with high affinity. Nearly all of the mechanistic work below comes from cell culture and animal models — the human read-through is strongest for topical skin, weakest for systemic injection.
| Mechanism | Detail |
|---|---|
| Copper delivery | GHK picks up copper from albumin and ferries it into cells, feeding copper-dependent enzymes involved in matrix cross-linking and antioxidant defense. The copper is arguably as active as the peptide itself. |
| Matrix & collagen synthesis | In fibroblast cultures GHK-Cu stimulates production of collagen, elastin, glycosaminoglycans and proteoglycans — the structural scaffolding of skin. This is the best-supported, most human-relevant action. |
| Wound healing & fibroblast repair | Restores function of damaged fibroblasts, supports angiogenesis, and accelerates closure in animal wound models. Much of the systemic-use enthusiasm extrapolates from this. |
| Antioxidant activity | Increases antioxidant enzyme activity and quenches reactive carbonyl species in biochemical and cell-based findings. |
Evidence Summary
The honest split here is topical versus injected. GHK-Cu has real, replicated human cosmetic evidence when applied to skin. The injected use that dominates peptide forums rests almost entirely on in-vitro and animal data plus anecdote.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Topical skin aging | Improved firmness, fewer fine lines | Human (topical) | Controlled cosmetic studies; effect sizes modest but real and repeated. |
| Topical collagen density | Increased skin collagen density | Human (topical) | Supports the collagen-synthesis mechanism in living human skin. |
| Wound healing | Strong animal data, thin human | Animal > human | Frequently cited to justify injection; the human bridge is weak. |
| Hair / follicle support | Early signals | Preliminary | Popular topical claim; evidence remains limited. |
| Systemic / injected benefits | No robust human trials | Anecdote | The gap between marketing and injected human evidence is largest here. |
| Human clinical trials | Topical RCTs yes; injected no | Human (injected) | Injectable use is unstudied in controlled human settings. |
Divergence — What This Means
Where the label meets the needle.
Topically, GHK-Cu is a legitimate, decades-studied cosmetic ingredient with human data behind it. That credibility gets transferred, often uncritically, to subcutaneous injection — where the supporting human evidence essentially disappears.
The community reads “proven collagen and repair peptide” and assumes injecting must be at least as good as applying it. But delivery, dose, systemic copper exposure and safety are entirely different questions once you leave the skin surface. Divergence is Moderate only because the underlying repair biology is real; “it works on skin” is not evidence that “injecting it works.”
The community reads “proven collagen and repair peptide” and assumes injecting must be at least as good as applying it. But delivery, dose, systemic copper exposure and safety are entirely different questions once you leave the skin surface. Divergence is Moderate only because the underlying repair biology is real; “it works on skin” is not evidence that “injecting it works.”
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Topical (cosmetic)
~0.05–2%
concentration in serums; the evidence-backed route
Injected (community, RUO)
~1–2 mg
reported SC daily; not clinically validated
Cycling (injected)
~4–8 wks on
common self-reported structure; arbitrary
Copper monitoring
Baseline labs
some users check copper with long-term use
Topical concentrations are cosmetic-formulation figures, not medical doses. Injected figures are community-reported for research use only and carry no established safe or effective dose. Copper is biologically active and cumulative — more is not better.
Safety Profile
Topical GHK-Cu has a long, generally reassuring cosmetic safety record. The unknowns concentrate on injected, systemic exposure — especially anything involving repeated copper loading.
Animal / preclinical — signals observed
Topical: occasional local irritation, redness or contact sensitivity
Injection-site redness or irritation with subcutaneous use
Copper is a bioactive metal; repeated systemic dosing raises copper-balance questions
Generally well tolerated at cosmetic topical concentrations
What is not known (human)
Long-term safety of injected GHK-Cu in humans is unstudied
Whether repeated injection causes copper accumulation is unresolved
No established systemic dose, frequency or ceiling
Interactions with copper-metabolism disorders (Wilson’s disease should avoid)
Purity and copper content vary across RUO sources
Not medical advice. Injectable GHK-Cu is sold research-use-only and is not an approved drug. Do not treat the cosmetic topical safety record as clearance for injection.
Regulatory Status — Updated July 2026
Flagged for reconsideration, not yet reviewed
GHK-Cu was not part of the July 23–24, 2026 PCAC meeting. It was named among peptides flagged for possible reconsideration in 2026, but it has not been formally reviewed or voted on and remains pending a future round. It is currently sold as a research-use-only injectable and as an over-the-counter cosmetic ingredient topically. Track current status →
Where to Source
Source research-grade GHK-Cu
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source GHK-Cu.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. GHK-Cu was not on the July 23–24, 2026 PCAC agenda and was not voted on. It was listed among peptides flagged for potential reconsideration, but no formal review has happened. It remains pending a future round.
Topical GHK-Cu is a well-studied cosmetic ingredient with real human skin evidence. Injected GHK-Cu is what the peptide community uses for systemic “repair” goals — and it has essentially no controlled human evidence. Same molecule, very different evidence base.
In skin, topically, the evidence is genuinely supportive: fibroblast studies and human cosmetic trials point to increased collagen and matrix production. Whether injecting it produces meaningful systemic benefit is a separate, largely unanswered question.
Potentially, with injection. Topical use delivers tiny amounts. Repeated subcutaneous dosing introduces bioactive copper systemically, and long-term copper balance in injected users is not well studied. People with Wilson’s disease or copper-metabolism disorders should avoid it.
Compare GHK-Cu